Jeffrey Crowley, MD, MS

IL-17 Inhibition and Long-Term Outcomes in Psoriasis

In this episode, ‘IL-17 Inhibition and Long-Term Outcomes in Psoriasis,’ the panelists provide a deeper exploration of IL-17–targeted therapies in psoriasis, focusing on the biological rationale behind different mechanisms of action and how these translate into clinical outcomes. The faculty explored the distinction between selective IL-17A inhibition and dual inhibition of IL-17A and IL-17F, highlighting the evolving understanding of the IL-17 cytokine family and its role in driving inflammation. While IL-17A has historically been considered the primary therapeutic target, emerging insights suggest that IL-17F may also play a significant role due to its higher abundance in psoriatic lesions, raising the possibility that broader pathway inhibition may offer additional clinical benefit.

The faculty examined the complexities of interpreting long-term efficacy data across therapies. While individual clinical trials demonstrate sustained responses over multiple years, they emphasized that differences in study design, patient populations, and statistical methodologies make cross-trial comparisons challenging. Factors such as responder enrichment, rescue criteria, and analytic approaches can significantly influence reported outcomes, underscoring the need for careful interpretation of long-term extension data.

Additionally, the panelists explore the role of real-world evidence as a complementary perspective to clinical trial findings. Although real-world data may introduce variability, it can provide valuable insights into treatment durability and performance in broader patient populations. They also highlight both the benefits and limitations of evaluating therapies aimed at achieving sustained remission in psoriasis.

The next episode in this series, ‘Rapid Response in Psoriasis Treatment,’ the panelists examine the role of rapid treatment response in psoriasis and how speed of efficacy influences treatment decisions and patient satisfaction. It highlights differences within IL-17 inhibitors and the ability to achieve both rapid and sustained disease control without compromising outcomes.

Videos

Expert panel weighs IL‑17 vs IL‑23 biologics for psoriasis, highlighting fast onset, durability, and why switching within class may work.

Comparing Biologic Classes and Durability in Psoriasis

This episode, titled ‘Comparing Biologic Classes and Durability in Psoriasis,’ features panelists discussing how different biologic classes compare in achieving and sustaining remission in psoriasis, with a focus on both speed and durability of response. The faculty discussed how treatment paradigms have evolved as head-to-head clinical trial data have emerged, allowing for more direct comparisons between classes such as IL-17 and IL-23 inhibitors. Historically, IL-17 inhibitors have been associated with rapid onset of action, while IL-23 inhibitors have demonstrated durable long-term responses.

The expert faculty highlight that not all agents within a biological class perform identically. Differences in efficacy and durability within the same class have become more apparent through direct comparisons, prompting clinicians to reconsider traditional approaches to treatment sequencing. Rather than automatically switching to a different class when a patient has an inadequate response, there may be value in selecting another agent within the same class.

They emphasize the growing importance of nuanced, evidence-based decision-making in psoriasis care. With an expanding array of therapeutic options, clinicians must consider not only class-level characteristics but also individual drug performance. Ultimately, the discussion reinforces that both achieving and maintaining disease control along with personalized treatment strategies are essential for optimizing long-term outcomes.

In the next episode, ‘IL-17 Inhibition and Long-Term Outcomes in Psoriasis,’ the panelists explore the mechanistic differences within IL-17 inhibition and their implications for treatment outcomes in psoriasis. It also highlights the challenges of interpreting long-term clinical trial and real-world data when evaluating sustained disease control.

Treatment Selection in Psoriasis

In ‘Treatment Selection in Psoriasis,’ our panelists focus on the growing body of long-term data supporting sustained disease control and remission in psoriasis, while also highlighting how these data inform real-world treatment selection. The expert faculty discuss emerging evidence demonstrating that a proportion of patients can achieve and maintain complete skin clearance over several years of continuous therapy. This concept of sustained remission is framed as a more stringent and clinically relevant outcome.

The discussion also explores how long-term durability data translate into everyday clinical treatment decisions. With an expanding number of biologic therapies available, clinicians must navigate the choices within limited patient visit times. The faculty highlights the importance of considering individual patient characteristics, such as comorbidities, body weight, presence of psoriatic arthritis, and treatment history, when selecting the most appropriate therapy.

Additionally, the panelists address the evolving expectations around treatment performance, including speed of response, depth of clearance, and durability. The ability to achieve both fast and sustained results is recognized as a key driver of patient satisfaction and quality of life. They also touch on practical considerations, such as dose adjustments and payer dynamics, which can influence treatment selection in real-world settings. The discussion underscores the shift toward personalized, data-driven decision-making in psoriasis care, where long-term outcomes and patient-specific factors guide the pursuit of sustained remission.

Our next episode, ‘Comparing Biologic Classes and Durability in Psoriasis,’ the faculty compares biologic classes in psoriasis, focusing on differences in speed of response and long-term durability. It highlights how emerging head-to-head data and within-class differences are shaping more individualized treatment decisions.

New psoriasis data show durable, rapid skin clearance with modern biologics, spotlighting bimekizumab’s four-year remission and patient-tailored selection.

Understanding Biologic Therapies in Psoriasis

In this episode, ‘Understanding Biologic Therapies in Psoriasis,’ the expert dermatologistsexplore the evolving landscape of biologic therapies in psoriasis, focusing on the key differences between therapeutic classes and the clinical importance of having multiple targeted treatment options. The faculty discussed how advances in the understanding of psoriasis pathophysiology, particularly the central IL-23/IL-17 inflammatory pathways have enabled the development of more precise and effective therapies compared with earlier biologics such as TNF-α inhibitors.

The panelists highlighted how first-generation biologics, while effective, were less targeted and associated with broader immune effects, requiring more extensive monitoring and consideration of off-target risks. As newer therapies have emerged, including IL-12, IL-23, and IL-17 inhibitors, clinicians have gained the ability to more selectively modulate the immune system. This has led to improvements in efficacy, safety, and overall treatment outcomes.

The faculty also examined the nuanced differences between targeting upstream versus downstream pathways, including variations in onset of action, durability of response, and potential effects on comorbid conditions such as inflammatory bowel disease. These distinctions underscore why multiple biologic classes are necessary, as no single therapy is optimal for all patients. They emphasized how a clearer understanding of disease biology enhances patient communication. By explaining psoriasis as a dysregulation of a specific immune pathway, clinicians can help patients better understand how targeted therapies work while reassuring them that broader immune function is preserved. Overall, this discussion reinforces the value of personalized treatment selection in modern psoriasis care.

The next episode in this series, ‘Treatment Selection in Psoriasis,’ features the panelists examining long-term data supporting sustained remission in psoriasis and how these findings influence clinical confidence in treatment durability. It also highlights how clinicians incorporate patient characteristics and real-world considerations when selecting biologic therapies to achieve long-term disease control.

Explore how psoriasis biologics differ—TNF vs IL‑23/IL‑17—why classes matter, and what targeted therapy means for safety and results.

Jeffrey Crowley, MD, MS

Articles